SABS
SAB Biotherapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
No thesis.
—
SAB Biotherapeutics, Inc.
3.34
Fund move
Fund move
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | Caligan PartnersCaligan Partners | $31.1M | 11.58% | 0.00% | |
| 2 | Vivo CapitalVivo Capital | $28.5M | 10.61% | −36.08% | |
| 3 | Perceptive AdvisorsPerceptive | $25.8M | 9.63% | +3.04% | |
| 4 | Adage Capital Partners GPAdage Capital Partners GP | $25.0M | 9.31% | +88.09% | |
| 5 | RA Capital ManagementRA Capital Management | $17.2M | 6.40% | 0.00% | |
| 6 | Balyasny Asset ManagementBalyasny | $14.7M | 5.47% | 0.00% | |
| 7 | BlackRockBlackRockindex-like | $12.0M | 4.46% | +917.51% | |
| 8 | Vanguard Capital ManagementVanguardindex-like | $11.6M | 4.32% | +19.22% | |
| 9 | Commodore CapitalCommodore Capital | $11.2M | 4.17% | −34.79% | |
| 10 | Millennium ManagementMillennium | $10.7M | 4.00% | −9.35% | |
| 11 | Spruce Street CapitalSpruce Street Capital | $8.6M | 3.20% | 0.00% | |
| 12 | Sessa Capital IMSessa Capital IM | $8.6M | 3.20% | 0.00% | |
| 13 | Affinity Asset AdvisorsAffinity Asset | $5.9M | 2.22% | +165.22% | |
| 14 | Boothbay Fund ManagementBoothbay Fund | $5.8M | 2.15% | 0.00% | |
| 15 | Geode Capital ManagementGeodeindex-like | $5.0M | 1.86% | +322.86% | |
| 16 | Woodline PartnersWoodline Partners | $4.6M | 1.72% | −58.61% | |
| 17 | Ensign Peak AdvisorsEnsign Peak | $4.6M | 1.70% | −14.75% | |
| 18 | Propel Bio ManagementPropel Bio | $4.2M | 1.57% | +6.30% | |
| 19 | Soleus Capital ManagementSoleus | $3.5M | 1.31% | −14.29% | |
| 20 | Seven Fleet Capital ManagementSeven Fleet | $2.9M | 1.07% | +636.08% | |
| 21 | Ameriprise FinancialAmeriprise Financial | $2.4M | 0.89% | −58.61% | |
| 22 | State StreetState Streetindex-like | $2.1M | 0.77% | +615.11% | |
| 23 | Susquehanna International GroupSusquehanna International | $1.8M | 0.68% | +917.24% | |
| 24 | DV EquitiesDV Equities | $1.6M | 0.58% | new | |
| 25 | AWM InvestmentAWM Investment | $1.5M | 0.55% | −6.25% |
87 managers report $268.3M of SAB Biotherapeutics on form 13F for the quarter ended Jun 30 '26. 14 of them hold 80% of it; Caligan Partners is largest at 11.58%.
Linked news
No implied move.
No implied move.
Expected move
No implied move.